SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (3151)1/4/2018 12:25:18 PM
From: Miljenko Zuanic  Respond to of 3202
 
And there was good rationale to go after malignant brain tumor (probably not with monotherapy):

ncbi.nlm.nih.gov

I guess, key point is "intratumoral"?



To: Miljenko Zuanic who wrote (3151)1/4/2018 12:30:27 PM
From: tuck1 Recommendation

Recommended By
scaram(o)uche

  Read Replies (1) | Respond to of 3202
 
The main differentiating characteristic of the iTeos compound was its penetration into the brain. Unfortunately, IDO apparently isn't really a good target for brain tumors per this guy:

TDO better target

iTeos talks of a TDO2 program, but nothing shows in their pipeline about it.

Cheers, Tuck


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News